PLX Earnings Protalix BioTherapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–31 of 31
| Q2 2026 | 2026-06-30 | 0.27 | 2026-08-12 | 10-Q |
| Q1 2026 | 2026-03-31 | 0.22 | 2026-05-13 | 10-Q |
| FY 2025 | 2025-12-31 | -0.08 | 2026-03-18 | 10-K |
| Q3 2025 | 2025-09-30 | -0.01 | 2025-11-13 | 10-Q |
| Q2 2026 | 2025-06-30 | -0.04 | 2026-08-12 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.05 | 2026-05-13 | 10-Q |
| FY 2025 | 2024-12-31 | 0.04 | 2026-03-18 | 10-K |
| Q3 2025 | 2024-09-30 | -0.05 | 2025-11-13 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.09 | 2025-08-14 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.06 | 2025-05-09 | 10-Q |
| FY 2025 | 2023-12-31 | 0.09 | 2026-03-18 | 10-K |
| Q3 2024 | 2023-09-30 | 0.16 | 2024-11-14 | 10-Q |
| Q2 2024 | 2023-06-30 | 0.18 | 2024-08-14 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.05 | 2024-05-10 | 10-Q |
| FY 2024 | 2022-12-31 | -0.31 | 2025-03-17 | 10-K |
| Q3 2023 | 2022-09-30 | -0.24 | 2023-11-06 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.16 | 2023-08-07 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.05 | 2023-05-04 | 10-Q |
| FY 2023 | 2021-12-31 | -0.62 | 2024-03-14 | 10-K |
| Q3 2022 | 2021-09-30 | -0.48 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.39 | 2022-08-15 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.14 | 2022-05-16 | 10-Q |
| FY 2022 | 2020-12-31 | -0.22 | 2023-02-27 | 10-K |
| Q3 2021 | 2020-09-30 | -0.25 | 2021-11-15 | 10-Q |
| FY 2021 | 2019-12-31 | -1.23 | 2022-03-31 | 10-K |
| Q2 2018 | 2018-06-30 | -0.11 | 2019-03-18 | 10-Q |
| Q2 2018 | 2017-06-30 | -0.47 | 2019-03-18 | 10-Q |
| Q2 2017 | 2016-06-30 | -0.20 | 2017-08-09 | 10-Q |
| Q2 2013 | 2013-06-30 | -0.12 | 2013-08-08 | 10-Q |
| Q2 2013 | 2012-06-30 | 0.04 | 2013-08-08 | 10-Q |
| Q2 2012 | 2011-06-30 | -0.22 | 2012-08-03 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.